Long-term antihypertensive treatment significantly increased flow-mediated dilation from 3.1% to 8.12% at 12 months (P<0.001), with nifedipine showing greater benefit than hydrochlorothiazide.
Observational (n=78)
Does antihypertensive treatment improve flow-mediated dilation of the brachial artery in patients with essential hypertension?
Effective long-term blood pressure reduction, particularly with calcium antagonists like nifedipine, improves impaired flow-mediated dilation in essential hypertension.
Tasa de eventos absoluta: 9.45% vs 4.69%
valor p: p=<0.001
off aim of our study was to evaluate the effect of antihypertensive treatment on flow-mediated dilation (FMD)of a large artery, a noninvasive estimate of endothelial function, in hypertensive patients. In 78 consecutive hypertensive patients (40%men; age range, 42 to 67 years) we measured by a high-resolution ultrasound system the changes of brachial artery diameter during reactive hyperemia and after sublingual glyceryl trinitrate (400 microg); brachial artery flow velocity was measured by pulsed Doppler. The results of 2 studies are reported. In the first study, this procedure was repeated in 58 patients after 6 and 12 months of treatment with a combination of antihypertensive drugs; in a second study, the FMD was assessed in 20 patients after 2 months of monotherapy with either nifedipine or hydrochlorothiazide. In the first study, FMD was significantly increased after treatment compared with baseline (from 3.1+/-3% at baseline to 6.5+/-4.5% at 6 months and to 8.12+/-4. 6% at 12 months; P<0.001 by ANOVA), concomitant with blood pressure reduction (from 162+/-24/102+/-13 mm Hg to 141+/-12/89+/-6 mm Hg and to 141+/-9/89+/-6 mm Hg; P<0.001 by ANOVA); significant changes of endothelium-independent dilation were also observed, but only after 12 months of treatment (from 14.2+/-4.8 at baseline to 15.5+/-4.7 at 6 months and 16.8+/-5.9% at 12 months; P=0.03 by ANOVA). In the second study, FMD was significantly increased during nifedipine treatment as compared with baseline (from 5+/-6.18% at baseline to 9. 45+/-3.94%, P<0.001), while it did not change in patients receiving hydrochlorothiazide (from 5.15+/-5.28% at baseline to 4.69+/-4.34%, NS). No significant changes of endothelium-independent dilation were observed with both drugs (from 17.10+/-2.4% to 18.14+/-3.76% and from 18.73+/-4.07% to 17.46+/-4.27% during nifedipine and hydrochlorothiazide, respectively, NS). Thus, in essential hypertensive patients an improvement of the impaired FMD of the brachial artery, evaluated by noninvasive ultrasound, may be observed after long-term, effective blood pressure reduction, suggesting a beneficial effect of antihypertensive treatment on endothelial function. It seems that beyond blood pressure control, a calcium antagonist may be more effective than a diuretic in this respect.
Muiesan et al. (Fri,) conducted a observational in Essential hypertension (n=78). Antihypertensive treatment (combination therapy or nifedipine) vs. Baseline or hydrochlorothiazide was evaluated on Flow-mediated dilation (FMD) of the brachial artery (p=<0.001). Long-term antihypertensive treatment significantly increased flow-mediated dilation from 3.1% to 8.12% at 12 months (P<0.001), with nifedipine showing greater benefit than hydrochlorothiazide.